trending Market Intelligence /marketintelligence/en/news-insights/trending/7r6y-mgbym_b6jsgtwxupg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

AMAG Pharmaceuticals sells Cord Blood Registry to PE firm GI Partners for $530M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


AMAG Pharmaceuticals sells Cord Blood Registry to PE firm GI Partners for $530M

AMAG Pharmaceuticals Inc., a U.S. developer of women's health treatments, is selling its Cord Blood Registry business to GI Partners LLC, a private equity firm, for $530 million in cash.

The Waltham, Mass.-based company will use most of the proceeds to pay off the remaining $475 million of principal on debt due in 2023. The transaction is expected to close in the third quarter and the company will update its 2018 financial guidance after that, AMAG said in a June 15 statement.

AMAG President and CEO William Heiden said the sale is key to the company's strategy to invest in and grow sales of its current therapies, which include anemia treatment Feraheme and Intrarosa for a menopause-related condition. The U.S. Food and Drug Administration has also accepted for review the company's application to market bremelanotide for female sexual dysfunction.

Cord Blood Registry, founded in 1992, stores umbilical cord blood samples from more than 600,000 children and has enabled more than 400 families to use the cells for both established and experimental therapies, according to its website.

San Francisco-based GI Partners said in a separate statement that it intends to combine Cord Blood Registry with California Cryobank Inc., a private donor sperm and egg bank. GI Partners did not disclose what it paid for California Cryobank.

Perella Weinberg Partners LP was AMAG's financial adviser, while Goodwin Procter LLP provided legal advice.